Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
Sapna P. Patel, Megan Othus, Yuanbin Chen, et al.
New England Journal of Medicine (2023) Vol. 388, Iss. 9, pp. 813-823
Open Access | Times Cited: 481

Showing 1-25 of 481 citing articles:

The cancer-immunity cycle: Indication, genotype, and immunotype
Ira Mellman, Daniel S. Chen, Thomas Powles, et al.
Immunity (2023) Vol. 56, Iss. 10, pp. 2188-2205
Open Access | Times Cited: 351
Cutaneous melanoma
Georgina V. Long, Susan M. Swetter, Alexander M. Menzies, et al.
The Lancet (2023) Vol. 402, Iss. 10400, pp. 485-502
Closed Access | Times Cited: 314
Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer
John V. Heymach, David H. Harpole, Tetsuya Mitsudomi, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 18, pp. 1672-1684
Open Access | Times Cited: 276
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
Jeffrey S. Weber, Matteo S. Carlino, Adnan Khattak, et al.
The Lancet (2024) Vol. 403, Iss. 10427, pp. 632-644
Closed Access | Times Cited: 249
Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy
Suzanne L. Topalian, Patrick M. Forde, Leisha A. Emens, et al.
Cancer Cell (2023) Vol. 41, Iss. 9, pp. 1551-1566
Open Access | Times Cited: 131
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
Christian U Blank, Minke W Lucas, Richard A. Scolyer, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 18, pp. 1696-1708
Closed Access | Times Cited: 126
Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair–Deficient Colon Cancer
Myriam Chalabi, Y.L. Verschoor, Pedro Batista Tan, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 21, pp. 1949-1958
Closed Access | Times Cited: 107
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges
Giannis Mountzios, Jordi Remón, Lizza E.L. Hendriks, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 10, pp. 664-677
Closed Access | Times Cited: 106
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Josep M. Llovet, Roser Pinyol, Mark Yarchoan, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 4, pp. 294-311
Closed Access | Times Cited: 103
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial
John M. Kirkwood, Michele Del Vecchio, Jeffrey S. Weber, et al.
Nature Medicine (2023) Vol. 29, Iss. 11, pp. 2835-2843
Open Access | Times Cited: 94
Systemic Therapy for Melanoma: ASCO Guideline Update
Rahul Seth, Sanjiv S. Agarwala, Hans Messersmith, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 30, pp. 4794-4820
Open Access | Times Cited: 90
Immunosurveillance in clinical cancer management
Guido Kroemer, Timothy A. Chan, Alexander M.M. Eggermont, et al.
CA A Cancer Journal for Clinicians (2023) Vol. 74, Iss. 2, pp. 187-202
Open Access | Times Cited: 62
Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial
Xu Liu, Yuan Zhang, Kun-Yu Yang, et al.
The Lancet (2024) Vol. 403, Iss. 10445, pp. 2720-2731
Closed Access | Times Cited: 47
IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma
Irene L. M. Reijers, Disha Rao, Judith M. Versluis, et al.
The Journal of Experimental Medicine (2023) Vol. 220, Iss. 5
Open Access | Times Cited: 45
Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now
Georgina V. Long, Alexander M. Menzies, Richard A. Scolyer
Journal of Clinical Oncology (2023) Vol. 41, Iss. 17, pp. 3236-3248
Closed Access | Times Cited: 42
Clinical and translational attributes of immune-related adverse events
Karijn P.M. Suijkerbuijk, Mick J M van Eijs, Femke van Wijk, et al.
Nature Cancer (2024) Vol. 5, Iss. 4, pp. 557-571
Closed Access | Times Cited: 36
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study
Mohamad E. Allaf, Se-Eun Kim, Viraj A. Master, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 8, pp. 1038-1052
Closed Access | Times Cited: 30
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial
Martin Schüler, Kristof Cuppens, Till Plönes, et al.
Nature Medicine (2024) Vol. 30, Iss. 6, pp. 1602-1611
Open Access | Times Cited: 29
Interruption of the intratumor CD8+ T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy
Shannon N. Geels, A. Moshensky, Rachel S. Sousa, et al.
Cancer Cell (2024) Vol. 42, Iss. 6, pp. 1051-1066.e7
Closed Access | Times Cited: 21
Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC
Yixin Zhou, Anlin Li, Hui Yu, et al.
JAMA Network Open (2024) Vol. 7, Iss. 3, pp. e241285-e241285
Open Access | Times Cited: 19
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial
Alexander M.M. Eggermont, Michal Kiciński, Christian U. Blank, et al.
European Journal of Cancer (2024) Vol. 211, pp. 114327-114327
Closed Access | Times Cited: 16
Checkpoint Inhibitors in Urothelial Carcinoma—Future Directions and Biomarker Selection
Joshua J. Meeks, Peter C. Black, Matthew D. Galsky, et al.
European Urology (2023) Vol. 84, Iss. 5, pp. 473-483
Open Access | Times Cited: 36
Neoadjuvant cemiplimab and surgery for stage II–IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study
Neil D. Gross, David M. Miller, Nikhil I. Khushalani, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 11, pp. 1196-1205
Closed Access | Times Cited: 34
Computational immunogenomic approaches to predict response to cancer immunotherapies
Venkateswar Addala, Felicity Newell, John V. Pearson, et al.
Nature Reviews Clinical Oncology (2023) Vol. 21, Iss. 1, pp. 28-46
Open Access | Times Cited: 34
Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma
Minke W. Lucas, Judith M. Versluis, Elisa A. Rozeman, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 6, pp. 408-422
Closed Access | Times Cited: 28
Page 1 - Next Page

Scroll to top